Safety and Continuity of Second- And Third-Line Therapy With Paclitaxel or Irinotecan for Advanced and Recurrent Gastric Cancer
Molecular and Clinical Oncology - United Kingdom
doi 10.3892/mco.2014.260
Full Text
Open PDFAbstract
Available in full text
Date
February 14, 2014
Authors
Publisher
Spandidos Publications